











































Non-steroidal anti-inflammatory drug use and outcomes of
COVID-19 in the ISARIC Clinical Characterisation Protocol UK
cohort
Citation for published version:
ISARIC4C Investigators 2021, 'Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the
ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study', The Lancet
Rheumatology, vol. 3, no. 7, pp. e498-e506. https://doi.org/10.1016/S2665-9913(21)00104-1,
https://doi.org/10.1016/S2665-9913(21)00104-1










Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
1 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) use and outcomes of COVID-19 in the ISARIC 
Clinical Characterisation Protocol UK cohort: A matched prospective cohort study.  
Thomas M Drake1, Cameron J Fairfield1, Riinu Pius1, Stephen R Knight1, Lisa Norman1, Michelle 
Girvan2, Hayley E. Hardwick3, Annemarie B Docherty1, Ryan S Thwaites4, Peter JM Openshaw4, J 
Kenneth Baillie5, Ewen M Harrison**1, Malcolm G Semple**3,6, for ISARIC4C Investigators* 
1. Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK 
2. Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK 
3. Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, 
Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of 
Liverpool, Liverpool, UK 
4. National Heart and Lung Institute, Imperial College London, UK 
5. Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, UK 
6. Department of Respiratory Medicine, Alder Hey Children’s Hospital, Liverpool, UK 
* = See names in supplementary authorship list. 
** = Joint last authors 
Correspondence to: 
Professor Ewen M Harrison 
Centre for Medical Informatics 
Usher Institute 
University of Edinburgh 
EH16 4UX 
Email: ewen.harrison@ed.ac.uk 




Running title: NSAIDs and outcomes in COVID-19 
Keywords: Non-steroidal anti-inflammatory drugs; NSAIDs; COVID-19; SARS-n-CoV-2 
Abstract word count: 349 




Research in context 
Evidence in context 
There have been anecdotal reports that use of non-steroidal anti-inflammatory drugs (NSAIDs) is linked 
to COVID-19 severity and poor outcomes. NSAIDs are an important analgesic class, used in the 
management of acute pain and rheumatological diseases. Several studies, in a variety of populations, 
have identified that patients taking NSAIDs who developSARS-CoV-2 infection are not at higher risk 
of hospitalisation or death. However, the populations included in these studies are frequently small, 
based on routine administrative data, or are drawn from community populations and hence have 
relatively low rates of SARS-CoV-2.  
Added value of this study 
This prospective, multicentre study from 255 UK healthcare facilities found that in patients who were 
hospitalised with COVID-19, those taking NSAIDs prior to admission had the same outcomes as those 
who did not. We did not find any differences in mortality, disease severity or in secondary outcomes 
including admission to critical care, use of ventilation, use of oxygen or presence of acute kidney injury. 
Implications of all the available evidence 
Those who are taking NSAIDs do not appear to have worse outcomes after COVID-19. Our prospective 
study contains the largest number of hospitalised COVID-19 patients, and significantly adds to the 
literature on the safety of NSAIDs and in-hospital outcomes. In the context of all the available evidence, 
NSAIDs do not appear to increase risk of hospitalisation or lead to worse in-hospital outcomes. NSAIDs 
are an important analgesic modality and have a vital opioid-sparing role in pain management. Patients 






Background: Reports suggested that existing use of non-steroidal anti-inflammatory drugs (NSAIDs) 
may lead to increased severity in patients with COVID-19. NSAIDs are an important analgesic, 
particularly in those with rheumatologic disease, and are widely available to the public without 
prescription. Evidence from community studies, administrative data and in small studies of hospitalised 
patients suggest NSAIDs are not associated with worse outcomes. 
Methods: Prospective, multicentre cohort study of patients hospitalised with COVID-19 in the UK 
between 17th January and 17th August 2020. The primary outcome was in-hospital mortality and 
secondary outcomes included disease severity at presentation, admission to critical care, receipt of 
invasive mechanical ventilation (IMV), receipt of noninvasive ventilation, use of supplementary oxygen 
and acute kidney injury. NSAID use was required to be within the 2 weeks prior to hospital admission. 
Logistic regression was used to estimate the effects of NSAIDs and adjust for confounding variables. 
Propensity score matching was used to further estimate effects of NSAIDS while accounting for 
covariate differences in populations. Effect estimates are presented as odds ratios (OR) with 
corresponding 95% confidence intervals. 
Results: 72,179 patients were included in the clinical characterisation protocol study across 255 
healthcare facilities. Of these, 4211 (5.8%) used NSAIDs prior to hospital admission. Following 
propensity score matching, balanced groups of NSAIDs and non-NSAIDs users were obtained (n = 
4205 each). On admission, there were no significant differences in severity between exposure groups. 
After adjusting for explanatory variables, NSAID use was not associated with worse overall survival 
(matched OR 0·95, 95% CI 0·84 to 1·07, p = 0·352), critical care admission (matched OR 1·01, 95% 
CI 0·87 to 1·17, p = 0·890), requirement for invasive ventilation (matched OR 0·96, 95% CI 0·80 to 
1·17, p = 0·694), requirement for noninvasive ventilation (matched OR 1·12, 95% CI 0·96 to 1·32, p = 
0·143), requirement for oxygen (matched OR 1·00, 95% CI 0·89 to 1·12, p = 0·968) or occurrence of 
acute kidney injury (matched OR 1 ·08, 95% CI 0·92 to 1·26, p = 0·330).  
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Non-steroidal anti-inflammatory drugs (NSAIDs) provide effective analgesia and are important in the 
treatment of inflammatory diseases. They form a part of the World Health Organisation’s (WHO) pain 
ladder and have opioid sparing properties, supported by data from randomised controlled trials1. In 
March 2020, the French health ministry and media discussed unpublished data that use of NSAIDs 
increased the severity of COVID-19 infection2,3. Debate ensued, with some arguing NSAIDs should 
be avoided as a result3–5. This led to several regulatory authorities calling for urgent investigations 
between NSAIDs and COVID-19 severity6. 
In SARS-CoV-2 infection, there have been recent studies which did not find any associations between 
NSAID use, hospitalisation and worse outcomes7–13. These studies have been conducted in a variety of 
different populations. In the community, administrative data have not identified an increased risk of 
hospitalisation for patients taking NSAIDs7,11,13. Data on hospitalised patients is scarcer, but suggest 
that patients taking NSAIDs do not have worse outcomes to those who are not on NSAIDs10–12. Studies 
which focus on hospitalised cohorts have included patients from single centres or have small numbers 
of patients taking NSAIDs. 
Studies of patients with non-SARS-CoV-2 respiratory infection have found associations between 
NSAID (including COX-2 inhibitors) use and increased rates of complications 14–19. These studies found 
NSAID use was associated with higher rates of myocardial infarction, pleural empyema and longer 
length of hospital stay. However, outcomes from these pneumonia studies, such as empyema are often 
less of a concern in patients with SARS-CoV-2 infection. Recognised safety concerns with the use of 
NSAIDs including increased incidence of stroke, gastrointestinal bleeding, myocardial infarction, acute 
kidney injury and bleeding 14–17,20, which are more common in the elderly. 
In contrast, a randomised control trial in the UK found ibuprofen reduced the symptom severity of acute 
respiratory tract infection of patients in the community21. In preclinical models, there is evidence that 
NSAIDs decrease pulmonary oedema, lessen endothelial leakiness, and reduce the severity of acute 
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respiratory distress syndrome (ARDS), leading to the suggestion they may be useful in the treatment of 
COVID-19 with at least one clinical trial currently underway22–24. 
The purpose of this study was to characterise the safety of NSAIDs and identify whether pre-existing 






The International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) Clinical 
Characterisation Protocol (CCP) for Severe Emerging Infection was developed in 2009 and activated 
in response to the SARS-CoV-2 pandemic on 17th January 2020. This is an actively recruiting, 
prospective cohort study recruiting across England, Scotland, and Wales. The protocol, revision history, 
case report forms, study information and consent forms are available online (https://isaric4c.net). Data 
and analysis scripts are available on request. ISARIC-CCP-UK received ethical approval from the South 
Central - Oxford C Research Ethics Committee in England (Ref: 13/SC/0149), and by the Scotland A 
Research Ethics Committee (Ref: 20/SS/0028). The study is reported in line with the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) guidelines25. 
Patients of all ages from 17th January up to the 17th August 2020 admitted to hospital with a confirmed 
or highly suspected SARS-CoV-2 infection leading to COVID-19 disease were eligible for inclusion in 
this study. Confirmation of SARS-CoV-2 was performed using reverse-transcriptase polymerase chain 
reaction (RT-PCR) and was the only testing modality available in the UK during the reported study 
period. Highly suspected cases were eligible for inclusion, given that SARS-CoV-2 was an emergent 
pathogen at time of protocol activation. We excluded patients who did not have death or discharge 
outcomes available. 
Data were collected by clinical research staff using a standardised case report form and entered into a 
Research Electronic Data Capture secure online database26. Data was captured across multiple 
timepoints, including at admission, during hospital stay (day 1, 3, 6 and 9) and discharge. Characteristics 
captured included age, biological sex, asthma, chronic cardiac disease, chronic haematologic disease, 
chronic kidney disease, chronic neurological disease, chronic non-asthmatic pulmonary disease, 
HIV/AIDs, malignancy, liver disease, obesity, rheumatologic disorder and smoking history. 
Physiological parameters at admission were captured, including components of the National Early 
Warning Score 2 (NEWS2) and the quick Sequential Organ Failure Assessment (qSOFA). 
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Current medication or medication taken within the past 2 weeks was recorded on hospital admission. 
The NSAID group was defined as patients taking generic or branded NSAIDs available within the UK, 
as determined using the NHS Technology Reference data Update Distribution Service, which were 
mapped to entered drug names within the study database. We defined exposure to NSAIDs as patients 
taking non-selective cyclooxygenase (COX) inhibitors or COX-2 specific inhibitors. Topical NSAID 
preparations were excluded. Aspirin was not considered an NSAID for the purposes of this analysis. 
The primary outcome was in-hospital mortality (including palliative discharge). Secondary outcomes 
included admission to critical care (Level 3 Intensive Care Unit or Level 2 High Dependency Unit); use 
of invasive mechanical ventilation (IMV); use of non-invasive ventilation (NIV); use of supplementary 
oxygen; and occurrence of acute kidney injury (AKI). AKI was defined according to the KDIGO 
guidelines27. Patients who were admitted after 3rd August 2020 were excluded to avoid bias from 
patients with a long-stay or who had not had adequate time to accrue secondary outcomes. 
Statistical Analysis 
Categorical data are presented as frequency and percentages. Normally distributed variables were 
summarised as mean (SD, standard deviation) and non-normally distributed variables as median (IQR, 
interquartile range). The Chi-square test was used to compare categorical data, except for where 
expected cell counts were 5 or fewer, where Fisher’s exact test was used. Continuous variables were 
compared using Welch’s T-test or the Kruskall-Wallis test, depending on the distribution of data. 
Propensity score matching was used to estimate the treatment effect of NSAIDs while accounting for 
covariate imbalance. This was done using a multistep approach. First, multiple imputation by chained 
equations was performed using available explanatory variables (age, sex, diabetes (type 1 or type 2), 
chronic cardiac disease, chronic renal disease, obesity, chronic pulmonary disease, ethnicity, dementia, 
and rheumatological disease) and outcomes (5 imputed datasets with 5 iterations per dataset; 
distributions checked graphically, and convergence confirmed). Second, logistic regression was used to 
determine the log odds of NSAID use (propensity scores) using the variables stated above. For logistic 
regression models, patient level explanatory variables were entered as fixed effects and in unmatched 
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models, hospital was used as a random effect. We did not use random effects for matched models to 
ensure we could match on clinical characteristics, rather than restrict matches to within each centre. 
Following this, propensity score matching was performed within each imputed dataset where patients 
on NSAIDs were matched 1:1 with their nearest neighbour not taking NSAIDs28. Balance was 
determined using standardised mean differences. Fourth, effects estimates were determined, and results 
pooled using Rubin’s rules29. Effect estimates are presented as odds ratios (OR) for binary outcome 
data, alongside their corresponding 95% confidence intervals. Imputed and matched data are presented 
as pooled models. 
For unmatched models, clinically plausible variables associated with NSAID use and clinical outcomes 
were incorporated into the modelling approach. These variables included age, sex, presence of chronic 
cardiac disease, chronic pulmonary disease, diabetes, obesity, chronic renal disease, rheumatological 
disease and dementia. First order interactions were checked prior to final model selection which was 
guided by minimisation of the Akaike Information Criterion (AIC). Statistical significance was taken 
at the level of P<0·05. Data were analysed using R version 3.6.3 (R Foundation for Statistical 
Computing, Vienna, AUT) using the tidyverse, finalfit, mice, MatchThem, cobalt and matchit packages. 
Sensitivity analysis 
We performed a sensitivity analysis including non-ibuprofen NSAIDs only, as these usually require a 
prescription in the UK and are more likely to be taken longer term than ibuprofen. We also undertook 
an analysis confined to patients with rheumatic disease, as this group are likely to be on long-term 
NSAIDs compared to others who may be taking NSAIDs for short-term analgesia. 
Role of the funding source 
The study sponsors and funders had no role in the study design, collection, analysis, data interpretation 
or report writing. TMD, RP, LN, JKB, ABD, MGS and EMH had access to the raw data. The 





Up to 10th August 2020, 78,674 patients were enrolled across 255 healthcare facilities in England, 
Scotland and Wales, representing around 60% of the total number of people admitted to hospital with 
COVID-19 over that time period. Of these, 72,179 patients had death outcomes available for matching. 
There did not appear to be large differences in distribution of explanatory variables by missing mortality 
outcome (appendix table 1). In this cohort 4211 (5·8%) were recorded as taking systemic NSAIDs prior 
to admission. In the unmatched data (table 1 and appendix table S2), patients who received NSAIDs 
were younger, more likely to be female and were significantly more likely to have pre-existing 
rheumatological disease. Propensity score matching produced balanced, well-matched treatment groups 
for each set of imputed and pooled models (appendix figure 1 and appendix tables S3-8). 
Disease severity at presentation 
On presentation to hospital, matched patients on NSAIDs had comparable qSOFA and NEWS2 scores 
to those who did not receive NSAIDs (figure 2). Use of NSAIDs was not associated with any differences 
in physiological scores or physiological parameters (table 3). 
Mortality and NSAID use 
The mortality rate was 30·4% (1279/4211) in the NSAIDs group and 31·3% (21,256/67,698) in the no 
NSAIDs group (supplementary figure 2). Unmatched outcomes including in-hospital mortality in our 
cohort are shown in table 2, where there were no significant differences in outcomes between NSAID 
and non-NSAID users. In a sensitivity analysis of patients admitted to hospital at least 7 days after 
symptom onset who were taking NSAIDs (19,734 /72,179) matched to patients not taking NSAIDs 
presenting in a similar time frame, there was no difference in survival (matched OR 1·11, 95% CI 0·88 
to 1·39, p = 0·374). In patients with rheumatologic disease (7,614/72,179), use of NSAIDs did not 
appear to be associated with increased mortality (matched OR 0·90, 95% CI 0·68 to 1·19, P = 0·444). 
Secondary outcomes and NSAID use 
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In the unmatched cohort NSAID users were slightly more likely to require non-invasive ventilation and 
sustain acute kidney injury (table 2). After matching, those taking NSAIDs were no more likely to 
require critical care, invasive mechanical ventilation, noninvasive ventilation or supplementary oxygen 
(table 3 and supplementary figure 2). When we did a sensitivity analysis, excluding those who died, our 
direction of findings did not change, and we did not observe any increase or decrease in associations 
between NSAIDs and any of the secondary outcomes (appendix table S9). A further two sensitivity 
analyses were performed to ensure around the secondary outcomes. First, we combined death and 
critical care outcomes together. Second, we went on to look at mortality in the population who did not 
require critical care. These analyses found showed no association between NSAIDs and the chances of 
death or admission to critical care when these were combined (OR 0·94, 95% CI 0·83 to 1·06, p = 
0·278) nor any association with death in patients who were not admitted to critical care (OR 0·92, 95% 
CI 0·82 to 1·03, p = 0·156). 
Differences in types of NSAIDs 
The commonest type of NSAIDs in use was ibuprofen, followed by “other” NSAIDs, 
diclofenac/ketorolac/naproxen, oxicams, and finally COX-2 inhibitors. There were no significant 
differences in mortality by type of NSAID (appendix table S10). As a sensitivity analysis to explore 
whether NSAIDs associated with longer term use had a different safety profile compared with 
ibuprofen, we created matched groups to compare ibuprofen with no NSAID use, and ibuprofen with 
other NSAIDs. Use of ibuprofen was not significantly associated with increased mortality compared 
with those on no NSAIDs (matched OR 0·90, 95% CI 0·71 to 1·13, P = 0·359, supplementary table 






In this study of 78,674 patients admitted to hospital with COVID-19, those who were taking NSAIDs 
did not have more severe disease than patients who were not on NSAIDs. Mortality, critical care 
admission, respiratory support and acute kidney injury were also comparable across matched NSAID-
treatment groups. We could not find evidence of harm NSAID use in patients admitted to hospital with 
severe COVID-19.  
Early in the pandemic, questions were raised around the safety of NSAIDs in patients with COVID-19, 
with suggestion that NSAIDs were leading to severe disease in a some patients 2,30,31.  Our data show 
patients taking NSAIDs did not have more severe symptoms or worse outcomes than those not taking 
NSAIDs. These data agree with community studies demonstrating NSAID users do not have higher 
rates of hospitalisation and smaller studies of in-hospital outcomes, which found NSAID use is not 
associated with worse outcomes. A recent, propensity matched data linkage study of patients with 
osteoarthritis taking NSAIDs in the community setting by Chandan et al., found no difference in the 
risk of developing COVID-19 or dying from it13. Compared with our data, and previous studies our 
consortium has published, the Chandan et al. study did not find any differences in risk factors for 
mortality following COVID-19, which is likely reflected by the very small numbers of patients with 
COVID-19 in their study13. Compared to the existing literature, we understand our study is the largest 
study of in-hospital outcomes of patients with COVID-19. In light of all the evidence, if there was an 
extreme effect of NSAIDs on COVID-19 outcomes or severity it would have likely been observed in 
one or more of the studies that have been performed, including ours. 
This is the largest prospective study of patients admitted to hospital in the world with COVID-19. We 
were able to collect real-time data on patients to study their outcomes and collect detailed comorbidity 
data. As part of this data collection, clinical research staff collected data on medications patients had 
been prescribed or were taking currently, or within the past 14 days. These data are otherwise 
challenging to obtain from routine sources of healthcare data. Whilst we have currently captured data 
on patients admitted to hospital with COVID-19, this only represents 60% of the hospitalised UK 
population over the course of the pandemic. This study did not capture patients who had disease which 
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could be managed in the community, or indeed disease progressing to palliation in the community 
without hospital admission. Despite this, it would be expected that most patients who had severe 
COVID-19 disease would be admitted to hospital and thus captured in our data. A further potential 
weakness of our study is the lack of information on the indication for NSAIDs and duration of use. This 
makes it difficult to know whether individuals were taking NSAIDs for long-term conditions, or 
symptomatic relief for COVID-19 symptoms. Similarly, it is unknown whether patients continued 
NSAIDs during their inpatient admission. Therefore, we are unable to make any recommendations on 
whether NSAIDs should be continued on admission to hospital. To address this, we performed a 
sensitivity analysis comparing ibuprofen to no NSAIDs or use of other non-ibuprofen NSAIDs, as 
ibuprofen use is most likely to be short-term. There was no increase in worse outcomes in the ibuprofen 
group compared with those who did not use NSAIDs. Similarly, it is possible that as older patients who 
are at greatest risk of adverse outcomes from COVID-19 are less likely to be taking NSAIDs than other, 
more healthy and fit populations, our matching may not have incorporated this patient group fully. But 
seeing as these patients are less likely to be taking NSAIDs and the safety debate is around younger 
populations, this is unlikely affect our results and their relevance to clinical practice.  
There are several other important limitations to our study that must be considered. First, the most used 
NSAID was ibuprofen, which may not be generalisable to every country. Different NSAIDs are well-
known to have different side-effect profiles, therefore clinical trials of a specific compound may not be 
generalisable to an entire drug class32. In addition to this, our data did not contain drug dosages or 
adherence data, so we were unable to model dose-response. Secondly, although our study captured data 
on the majority of patients hospitalised with COVID-19 in the UK over the time period it was 
conducted, a few centres did not participate. However, our data is concordant with other datasets 
focussed on smaller populations within our study, such as data from the Intensive Care National Audit 
and Research Centre (ICNARC)33. Therefore, we consider our data is meaningful and is useful to help 
answer important clinical questions in patients with COVID-19. Another limitation that should be 
considered is that in order to obtain the best possible matches for patients receiving NSAIDs, we did 
not include date of admission as a matching variable. Mortality for hospitalised patients over the course 
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of the pandemic has decreased, but this is unlikely to have affected our conclusions given the time 
period we conducted our study over was limited largely to the first UK wave of infection. Finally, our 
data lacks a non-SARS-CoV-2 comparator group to provide a temporal comparison with other critical 
illness or respiratory conditions. Future research may wish to include a comparator group to see if 
NSAIDs modify or moderate outcomes of interest in COVID-19 compared with other illnesses. 
Although use of NSAIDs could, in theory, be beneficial in patients with COVID-19, we did not identify 
any evidence to support this. Clinical studies have suggested release of proinflammatory mediators in 
COVID-19, including IL-1β, IL-6 and MCP-1, are associated with more severe COVID-19 disease34,35. 
Preclinical studies, in non-COVID-19 models, have found release of these cytokines can be inhibited 
by treatment with NSAIDs and has led to discussion around whether NSAIDs may be useful as a therapy 
for COVID-1923,36,37. In these studies, NSAIDs have been found to suppress IL-6 production and 
expression through a variety of mechanisms, including suppression of prostaglandin E2 which 
upregulates production of IL-6 and IL-836,37. Studies in bronchial epithelium have found that treatment 
with NSAIDs reduces expression of inflammatory mediators, including IL-636. A clinical trial of 
dexamethasone, which also has been shown to modulate inflammation38, albeit likely through a separate 
mechanism, has been shown to reduce mortality in COVID-19 patients. Other immunomodulatory 
therapies are currently being trialled, including the IL-6 inhibitor Tocilizumab. Results from the 
REMAP-CAP study, currently only available as a press release, has identified that Tocilizumab may 
reduce requirement for organ support and improve survival, with further trials underway39–41. In addition 
to these trials, a randomised trial of ibuprofen in patients with COVID-19 is also taking place23. 
For clinicians and patients, our findings should provide reassurance that NSAIDs can be used as 
indicated in the community without increasing the risk of severity of COVID-19. Our study did not 
capture whether NSAIDs were continued in-hospital, so we cannot make any recommendations on 
whether these should be withheld or continued. There are important groups of patients who rely on 
NSAIDs for pain relief, including those with inflammatory joint diseases, bone pain, gout, postoperative 
pain, and menstrual pain, who would otherwise have few non-opioid options for pain relief. Taken 
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together, clinicians should continue to prescribe and manage NSAIDs in the same way as before the 
SARS-CoV-2 pandemic began. 
Future research in this area should focus on whether NSAIDs sufficiently modulate inflammation in 
COVID-19, by using both basic science and clinical approaches which use appropriate outcomes which 
are directly measured. If benefit or harm is identified, finding the cellular mechanisms responsible for 
these effects will be important to inform the biological understanding of COVID-19 disease. Finally, 
including arms that compare NSAIDs to alternative analgesics should be considered, to provide 
evidence for clinicians and patients on the risks associated with alternative medications. Policy makers 
should consider reviewing issued advice around NSAID prescribing and COVID-19 severity 
considering our study. In conclusion, NSAID use is not associated with worse outcomes in hospitalised 
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Table 1 – Unmatched patient characteristics by NSAID use 
 Total N  No NSAIDs 
N = 67968 
NSAIDs 
N = 4211 
p 
Age on admission (years) 71987 Mean (SD) 70.2 (18.4) 70.1 (18.7) 0.765* 
Sex at Birth 71915 Male 38151 (56.1) 2255 (53.6) 0.001 
  Female 29564 (43.5) 1945 (46.2)  
  (Missing) 253 (0.4) 11 (0.3)  
Ethnicity 64123 Asian 3708 (5.5) 230 (5.5) 0.116 
  Black 2358 (3.5) 118 (2.8)  
  White 50124 (73.7) 3109 (73.8)  
  Other 4201 (6.2) 275 (6.5)  
  (Missing) 7577 (11.1) 479 (11.4)  
Smoking 43585 Yes 3588 (5.3) 228 (5.4) <0.001 
  Never Smoked 22896 (33.7) 1394 (33.1)  
  Former Smoker 14428 (21.2) 1051 (25.0)  
  (Missing) 27056 (39.8) 1538 (36.5)  
Chronic cardiac disease 67454 No 42831 (63.0) 2557 (60.7) <0.001 
  Yes 20588 (30.3) 1478 (35.1)  
  (Missing) 4549 (6.7) 176 (4.2)  
Chronic kidney disease 66964 No 51800 (76.2) 3237 (76.9) 0.042 
  Yes 11167 (16.4) 760 (18.0)  
  (Missing) 5001 (7.4) 214 (5.1)  
Chronic pulmonary 
disease (not asthma) 
67171 No 51933 (76.4) 3219 (76.4) 0.003 
  Yes 11232 (16.5) 787 (18.7)  
  (Missing) 4803 (7.1) 205 (4.9)  
Obesity (as defined by 
clinical staff) 
60199 No 49993 (73.6) 3039 (72.2) <0.001 
  Yes 6590 (9.7) 577 (13.7)  
  (Missing) 11385 (16.8) 595 (14.1)  
Diabetes 65135 No Diabetes 46728 (68.8) 2881 (68.4) 0.189 
  Diabetes with 
complications 
4484 (6.6) 299 (7.1)  
  Diabetes without 
complications 
10150 (14.9) 593 (14.1)  
  (Missing) 6606 (9.7) 438 (10.4)  
Rheumatologic disorder  66228 No 55469 (81.6) 3145 (74.7) <0.001 
  Yes 6809 (10.0) 805 (19.1)  
  (Missing) 5690 (8.4) 261 (6.2)  
Dementia 66788 No 51980 (76.5) 3368 (80.0) <0.001 
  Yes 10845 (16.0) 595 (14.1)  
  (Missing) 5143 (7.6) 248 (5.9)  
NSAIDs – Non-steroidal anti-inflammatory drugs, SD – Standard Deviation. All tests Chi-square 













N = 67968 
 
NSAIDs 
N = 4211 p 
Mortality 72179 0 No 46712 (68.7) 2932 (69.6) 0.227 
   Yes 21256 (31.3) 1279 (30.4)  
Critical Care Admission 70955 1224 No 57507 (86.1) 3599 (85.7) 0.467 
   Yes 9250 (13.9) 599 (14.3)  
Invasive Ventilation 69972 2207 No 60254 (91.5) 3821 (91.9) 0.396 
   Yes 5562 (8.5) 335 (8.1)  
Noninvasive 
Ventilation 69818 2361 No 55809 (85.0) 3452 (83.3) 0.005 
   Yes 9867 (15.0) 690 (16.7)  
Supplemental Oxygen 70124 2055 No 22826 (34.6) 1420 (34.2) 0.620 
   Yes 43147 (65.4) 2731 (65.8)  
Acute Kidney Injury 68228 3951 No 48258 (75.1) 2945 (73.6) 0.034 
   Yes 15970 (24.9) 1055 (26.4)  
 
NSAIDs – Non-steroidal anti-inflammatory drugs. All tests Chi-square.  
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Table 3 – Outcomes following propensity score matching between those using NSAIDs prior to 
admission and those not using NSAIDs. 





Matched odds ratio (95% CI, p-value) 
In-hospital 
mortality 
No NSAIDs   1 (Reference level) 
NSAIDs In-hospital mortality (4205:4205) 0.95 (0.84 to 1.07, p = 0.352) 
    Matched odds ratio (95% CI, p-value) 
Secondary 
outcomes 
No NSAIDs   1 (Reference level) 
NSAIDs Critical care admission  (4198:4198) 1.01 (0.87 to 1.17, p = 0.890) 




 (4142:4142) 1.12 (0.96 to 1.32, p = 0.143) 
 Oxygen  (4151:4151) 1.00 (0.89 to 1.12, p = 0.968) 
 Acute Kidney Injury  (4000:4000)  1.08 (0.92 to 1.26, p = 0.330) 






qSOFA score  (3793:3793) -0.02 (-0.06 to 0.02, p = 0.423) 
NEWS score  (3721:3721) -0.08 (-0.30 to 0.14, p = 0.461) 
Physiological 
parameters 
Heart rate  (4102:4102) -0.40 (-1.39 to 0.59, p = 0.432) 
Respiratory rate  (4096:4096) -0.17 (-0.66 to 0.32, p = 0.478) 
SpO2  (4076:4076) -0.00 (-0.27 to 0.26, p = 0.980) 
Systolic blood pressure  (4085:4085) 1.09 (-0.07 to 2.25, p = 0.066) 
Diastolic blood 
pressure 
 (4071:4071) -0.21 (-0.93 to 0.51, p = 0.563) 
 
CI – Confidence Interval, qSOFA – quick Sequential Organ Failure Assessment, SpO2 – saturation of 






Figure 1 – Study inclusion flowchart 
  Patients included up to 17th August 2020 
N = 78,674 
Patients with mortality outcome available for 
matching 
N = 72,179 
Number of patients 
using NSAIDs 
N = 4,211 
Number of patients 
not using NSAIDs 
N = 67,968 
Number of patients 
using NSAIDs with 
variables available 
for matching for 
primary outcome 
(mortality) 
N = 4,205  
Number of patients 
not using NSAIDs 
matched 1:1 for 
primary outcome 
(mortality) 
N = 4,205 
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Figure 2 – Distribution of physiological parameters on admission by NSAID use in matched, 


















BP – Blood pressure, NEWS – National Early Warning Score 2, NSAIDs – Non-steroidal anti-





Table S1 – Missing data analysis 
Missing data analysis: 
Death   Not missing Missing 
Age (years) <50 9938 (13.8) 416 (16.7) 
 50-69 19534 (27.1) 679 (27.3) 
 70-79 16099 (22.4) 557 (22.4) 
 80+ 26419 (36.7) 838 (33.7) 
Sex Male 40406 (56.2) 1414 (56.4) 
 Female 31509 (43.8) 1093 (43.6) 
Chronic Cardiac 
Disease No 45388 (67.3) 1147 (66.8) 
 Yes 22066 (32.7) 569 (33.2) 
Chronic Pulmonary 
Disease No 55152 (82.1) 1382 (81.5) 
 Yes 12019 (17.9) 314 (18.5) 
Diabetes No Diabetes 49609 (76.2) 1255 (76.3) 
 Diabetes with complications 4783 (7.3) 110 (6.7) 
 Diabetes without complications 10743 (16.5) 279 (17.0) 
Obesity No 53032 (88.1) 1380 (90.1) 
 Yes 7167 (11.9) 151 (9.9) 
Chronic Kidney Disease No 55037 (82.2) 1389 (82.4) 
 Yes 11927 (17.8) 296 (17.6) 
Rheumatic Disease No 58614 (88.5) 1506 (91.3) 
 Yes 7614 (11.5) 143 (8.7) 
Dementia No 55348 (82.9) 1414 (84.7) 











Missing data   
Total N (%)    72179 (100.0) 
Age on admission 
(years) 71987 192 Mean (SD) 70.2 (18.4) 
Sex at Birth 71915 264 Male 40406 (56.2) 
   Female 31509 (43.8) 
Chronic cardiac disease 67454 4725 No 45388 (67.3) 
   Yes 22066 (32.7) 
Chronic kidney disease 66964 5215 No 55037 (82.2) 
   Yes 11927 (17.8) 
Chronic pulmonary 
disease (not asthma) 67171 5008 No 55152 (82.1) 
   Yes 12019 (17.9) 
Obesity (as defined by 
clinical staff) 60199 11980 No 53032 (88.1) 
   Yes 7167 (11.9) 
Diabetes 65135 7044 Diabetes with complications 4783 (7.3) 
   Diabetes without complications 10743 (16.5) 
   No Diabetes 49609 (76.2) 
Rheumatologic disorder  66228 5951 No 58614 (88.5) 
   Yes 7614 (11.5) 
Dementia 66788 5391 No 55348 (82.9) 




Table S3- Summary of matched imputed datasets for mortality outcome 
  No NSAIDs NSAIDs 
Age (years) <50 537 (12.77) 540 (12.84) 
 50-69 1199 (28.51) 1198 (28.50) 
 70-79 958 (22.78) 954 (22.69) 
 80+ 1512 (35.95) 1512 (35.97) 
Sex at birth Female 2256 (53.65) 2255 (53.63) 
 Male 1949 (46.35) 1950 (46.37) 
Chronic Cardiac 
Disease No 2667 (63.42) 2668 (63.45) 
 Yes 1538 (36.58) 1537 (36.55) 
Diabetes Mellitus No Diabetes 3196 (76.00) 3194 (75.96) 
 Diabetes with complications 343 (8.16) 346 (8.23) 
 Diabetes without complications 666 (15.84) 665 (15.81) 
Obesity No 3537 (84.11) 3536 (84.09) 
 Yes 668 (15.89) 669 (15.91) 
Chronic Kidney Disease No 3402 (80.90) 3400 (80.86) 
 Yes 803 (19.10) 805 (19.14) 
Rheumatic disease No 3339 (79.41) 3339 (79.41) 
 Yes 866 (20.59) 866 (20.59) 
Dementia No 3571 (84.92) 3568 (84.85) 
 Yes 634 (15.08) 637 (15.15) 
Outcome (not included in matching)   
Death Alive 2881 (68.51) 2932 (69.73) 




Table S4- Summary of matched imputed datasets for critical care outcome 
  No NSAIDs NSAIDs 
Age (years) <50 533 (12.70) 537 (12.79) 
 50-69 1200 (28.59) 1199 (28.55) 
 70-79 954 (22.73) 954 (22.72) 
 80+ 1510 (35.98) 1509 (35.94) 
Sex at birth Male 2254 (53.69) 2253 (53.67) 
 Female 1944 (46.31) 1945 (46.33) 
Chronic Cardiac 
Disease No 2660 (63.36) 2662 (63.41) 
 Yes 1538 (36.64) 1536 (36.59) 
Diabetes Mellitus No Diabetes 3186 (75.89) 3186 (75.89) 
 Diabetes with complications 341 (8.12) 344 (8.19) 
 Diabetes without complications 671 (15.98) 668 (15.91) 
Obesity No 3528 (84.04) 3526 (83.99) 
 Yes 670 (15.96) 672 (16.01) 
Chronic Kidney Disease No 3386 (80.66) 3386 (80.66) 
 Yes 812 (19.34) 812 (19.34) 
Rheumatic disease No 3337 (79.49) 3337 (79.49) 
 Yes 861 (20.51) 861 (20.51) 
Dementia No 3567 (84.97) 3562 (84.85) 
 Yes 631 (15.03) 636 (15.15) 
Outcome (not included in matching)   
Critical care admission No 3604 (85.85) 3599 (85.73) 




Table S5- Summary of matched imputed datasets for invasive ventilation outcome 
  No NSAIDs NSAIDs 
Age (years) <50 529 (12.73) 533 (12.82) 
 50-69 1190 (28.63) 1188 (28.59) 
 70-79 945 (22.74) 946 (22.76) 
 80+ 1492 (35.90) 1489 (35.83) 
Sex at birth Male 2229 (53.63) 2227 (53.59) 
 Female 1927 (46.37) 1929 (46.41) 
Chronic Cardiac 
Disease No 2639 (63.50) 2643 (63.59) 
 Yes 1517 (36.50) 1513 (36.41) 
Diabetes Mellitus No Diabetes 3152 (75.84) 3153 (75.87) 
 Diabetes with complications 344 (8.28) 344 (8.28) 
 Diabetes without complications 660 (15.88) 659 (15.86) 
Obesity No 3490 (83.97) 3488 (83.93) 
 Yes 666 (16.03) 668 (16.07) 
Chronic Kidney Disease No 3357 (80.77) 3356 (80.75) 
 Yes 799 (19.23) 800 (19.25) 
Rheumatic disease No 3309 (79.62) 3308 (79.60) 
 Yes 847 (20.38) 848 (20.40) 
Dementia No 3533 (85.01) 3528 (84.89) 
 Yes 623 (14.99) 628 (15.11) 
Outcome (not included in matching)   
Invasive mechanical 
ventilation No 3805 (91.55) 3821 (91.94) 




Table S6- Summary of matched imputed datasets for non-invasive ventilation outcome 
  No NSAIDs NSAIDs 
Age (years) <50 528 (12.75) 532 (12.84) 
 50-69 1186 (28.63) 1183 (28.56) 
 70-79 945 (22.82) 945 (22.82) 
 80+ 1483 (35.80) 1482 (35.78) 
Sex at birth Male 2226 (53.74) 2224 (53.69) 
 Female 1916 (46.26) 1918 (46.31) 
Chronic Cardiac 
Disease No 2627 (63.42) 2628 (63.45) 
 Yes 1515 (36.58) 1514 (36.55) 
Diabetes Mellitus No Diabetes 3135 (75.69) 3133 (75.64) 
 Diabetes with complications 341 (8.23) 344 (8.31) 
 Diabetes without complications 666 (16.08) 665 (16.06) 
Obesity No 3479 (83.99) 3478 (83.97) 
 Yes 663 (16.01) 664 (16.03) 
Chronic Kidney Disease No 3341 (80.66) 3341 (80.66) 
 Yes 801 (19.34) 801 (19.34) 
Rheumatic disease No 3294 (79.53) 3294 (79.53) 
 Yes 848 (20.47) 848 (20.47) 
Dementia No 3520 (84.98) 3516 (84.89) 
 Yes 622 (15.02) 626 (15.11) 
Outcome (not included in matching)   
Noninvasive ventilation No 3496 (84.40) 3452 (83.34) 




Table S7- Summary of matched imputed datasets for supplemental oxygen outcome 
  No NSAIDs NSAIDs 
Age (years) <50 530 (12.77) 533 (12.84) 
 50-69 1190 (28.67) 1187 (28.60) 
 70-79 943 (22.72) 943 (22.72) 
 80+ 1487 (35.83) 1488 (35.85) 
Sex at birth Male 2237 (53.89) 2237 (53.89) 
 Female 1914 (46.11) 1914 (46.11) 
Chronic Cardiac 
Disease No 2635 (63.48) 2635 (63.48) 
 Yes 1516 (36.52) 1516 (36.52) 
Diabetes Mellitus No Diabetes 3146 (75.79) 3145 (75.76) 
 Diabetes with complications 341 (8.21) 344 (8.29) 
 Diabetes without complications 664 (16.00) 662 (15.95) 
Obesity No 3483 (83.91) 3482 (83.88) 
 Yes 668 (16.09) 669 (16.12) 
Chronic Kidney Disease No 3354 (80.80) 3354 (80.80) 
 Yes 797 (19.20) 797 (19.20) 
Rheumatic disease No 3295 (79.38) 3295 (79.38) 
 Yes 856 (20.62) 856 (20.62) 
Dementia No 3534 (85.14) 3529 (85.02) 
 Yes 617 (14.86) 622 (14.98) 
Outcome (not included in matching)   
Supplemental oxygen No 1419 (34.18) 1420 (34.21) 




Table S8- Summary of matched imputed datasets for acute kidney injury outcome 
  No NSAIDs NSAIDs 
Age (years) <50 420 (10.50) 423 (10.57) 
 50-69 1170 (29.25) 1168 (29.20) 
 70-79 936 (23.40) 936 (23.40) 
 80+ 1474 (36.85) 1473 (36.83) 
Sex at birth Male 2163 (54.07) 2161 (54.02) 
 Female 1837 (45.92) 1839 (45.98) 
Chronic Cardiac 
Disease No 2506 (62.65) 2508 (62.70) 
 Yes 1494 (37.35) 1492 (37.30) 
Diabetes Mellitus No Diabetes 3018 (75.45) 3019 (75.48) 
 Diabetes with complications 332 (8.30) 333 (8.33) 
 Diabetes without complications 650 (16.25) 648 (16.20) 
Obesity No 3352 (83.80) 3351 (83.78) 
 Yes 648 (16.20) 649 (16.23) 
Chronic Kidney Disease No 3219 (80.47) 3217 (80.42) 
 Yes 781 (19.53) 783 (19.57) 
Rheumatic disease No 3168 (79.20) 3167 (79.17) 
 Yes 832 (20.80) 833 (20.82) 
Dementia No 3385 (84.62) 3380 (84.50) 
 Yes 615 (15.38) 620 (15.50) 
Outcome (not included in matching)   
Acute Kidney Injury No 2980 (74.50) 2945 (73.62) 




Table S9 – Propensity matched secondary outcomes after excluding those who died  
Outcome 
Patients who were alive and 
had available data for matching 
(1:1) 
Effect estimate (Odds ratio, 
95%CI) 
No NSAIDs (Reference)  1 (reference level) 
Critical Care - NSAIDs (3376:3376) 0.91 (0.79 to 1.06, p = 0.243) 
Invasive ventilation - NSAIDs (3350:3350) 0.84 (0.67 to 1.07, p = 0.151) 
Non-invasive ventilation – 
NSAIDs (3338:3338) 0.99 (0.80 to 1.22, p = 0.896) 
Oxygen – NSAIDs (3340:3340) 0.96 (0.85 to 1.08, p = 0.517) 
AKI - NSAIDs (2915:2915) 0.97 (0.84 to 1.13, p = 0.712) 
 





Table S10 – Effect of different NSAIDs on mortality in patients with COVID-19 after adjustment for 
explanatory variables in an unmatched cohort. 
   Died Alive OR (univariable) OR (multilevel) 
NSAID type No NSAIDs 42042 (67.4) 20372 (32.6) - - 
 COX-2 Inhibitor 82 (75.9) 26 (24.1) 0.65 (0.41-1.00, p=0.060) 1.06 (0.64-1.77, p=0.822) 
 Diclofenac/ Ketorolac /Naproxen 186 (68.1) 87 (31.9) 0.97 (0.74-1.24, p=0.786) 1.10 (0.81-1.50, p=0.529) 
 
Ibuprofen (or similar 
propionic acid 
derivative) 
681 (74.9) 228 (25.1) 0.69 (0.59-0.80, p<0.001) 0.88 (0.73-1.06, p=0.188) 
 Mixed NSAIDs 551 (74.4) 190 (25.6) 0.71 (0.60-0.84, p<0.001) 1.14 (0.93-1.39, p=0.195) 




<50 9408 (94.7) 530 (5.3) - - 
 50-69 15526 (79.5) 4008 (20.5) 4.58 (4.17-5.04, p<0.001) 3.81 (3.38-4.30, p<0.001) 
 70-79 10181 (63.2) 5918 (36.8) 10.32 (9.41-11.34, p<0.001) 8.14 (7.22-9.18, p<0.001) 
 80+ 14395 (54.5) 12024 (45.5) 14.83 (13.55-16.25, p<0.001) 
12.14 (10.78-13.67, 
p<0.001) 
Sex at Birth Female 22647 (71.9) 8862 (28.1) - - 
 Male 26823 (66.4) 13583 (33.6) 1.29 (1.25-1.34, p<0.001) 1.42 (1.36-1.48, p<0.001) 
Chronic cardiac 
disease No 33429 (73.7) 11959 (26.3) - - 





No 39145 (71.0) 16007 (29.0) - - 
 Yes 7128 (59.3) 4891 (40.7) 1.68 (1.61-1.75, p<0.001) 1.24 (1.18-1.31, p<0.001) 
Chronic kidney 
disease No 39354 (71.5) 15683 (28.5) - - 




No 36603 (69.0) 16429 (31.0) - - 
 Yes 5194 (72.5) 1973 (27.5) 0.85 (0.80-0.89, p<0.001) 1.21 (1.13-1.29, p<0.001) 
Diabetes No Diabetes 35006 (70.6) 14603 (29.4) - - 
 Diabetes with complications 3088 (64.6) 1695 (35.4) 1.32 (1.24-1.40, p<0.001) 1.05 (0.97-1.14, p=0.191) 
 Diabetes without complications 6899 (64.2) 3844 (35.8) 1.34 (1.28-1.40, p<0.001) 1.19 (1.13-1.25, p<0.001) 
Rheumatologic 
disorder  No 40789 (69.6) 17825 (30.4) - - 
 Yes 4922 (64.6) 2692 (35.4) 1.25 (1.19-1.32, p<0.001) 0.94 (0.89-1.00, p=0.070) 
 NSAIDs – Nonsteroidal anti-inflammatory drugs, COX – Cyclooxygenase.   
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Table S11 - Sensitivity analysis of effect of Ibuprofen on in-hospital mortality, compared with no 
NSAIDs. 
Dependent Patients who were alive and had available data for matching (1:1) 
Effect estimate  
(Odds ratio, 95%CI) 
No NSAIDs (reference)  1 (reference level) 
Ibuprofen (721:721) 0.90 (0.71 to 1.13, p = 0.359) 
NSAIDs – Nonsteroidal anti-inflammatory drugs, 95% CI – 95% Confidence Interval.  
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Table S12 – Sensitivity analysis of effect of Ibuprofen on in-hospital mortality, compared with other 
NSAIDs. 
Outcome Patients who were alive and had available data for matching (1:1) 
Effect estimate  
(Odds ratio, 95%CI) 
Other NSAIDs (reference)  1 (reference level) 
Ibuprofen (908:908) 0.82 (0.66 to 1.03, p = 0.082) 








Supplementary Figure 2 – Outcomes in the unmatched cohort by age and NSAID use (y-axes scaled 
to reflect number of patients in each group).  
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